Skinvisible Q2 FY26 net loss narrows to USD 255,533; revenue flat at USD 5,000
Reuters2026/08/13 18:42- Skinvisible posted a net loss of USD 255,533 for Q2 2026, narrowing from a loss of USD 274,427 a year earlier.
- Revenue held flat at USD 5,000 versus the prior-year quarter, while operating expenses fell to USD 117,817 from USD 141,237.
- Interest expense drove other expenses of USD 142,716, little changed from USD 142,720 in the year-ago quarter.
- Working capital deficit widened to USD 5.5 million at June 30, 2026, from USD 4.99 million at Dec. 31, 2025.
- Quoin’s QRX003 remains on track for Phase 3 recruitment completion by end-2026, with a potential FDA filing targeted for 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
How will the 110 trillion KRW AI dividend be distributed? Seoul-based hedge fund pressures Samsung to immediately buy back and cancel preferred shares
A South Korean hedge fund is pressuring Samsung to buy back and cancel its preferred shares, planning to use 73 trillion won of a 110 trillion won return plan for the repurchase, aiming to eliminate a discount of over 25%.
Extreme level of 8,500 emerges! Two top strategists raise S&P 500 target as strong earnings become key support
Despite facing a surge in US Treasury yields surpassing 5% and a slowdown in the AI sector, Wall Street institutions continue to raise their S&P 500 target prices, with the most bullish forecasts reaching up to 8,500 points.
BIG Impact invests in autoimmune diagnostics and drug discovery startup AOI Biosciences
LG Electronics Gains a Bull on Likely 3Q Earnings Beat -- Market Talk
Crypto prices
More
